Get to know our clinical trials
Clinical trial to evaluate the efficacy and safety of tirbanibulin 10 mg/g ointment applied to a treatment field greater than 25 cm2 and up to 100 cm2 in adult patients with actinic keratosis.
THE MAIN OBJECTIVE OF THE PRESENT STUDY IS TO EVALUATE HOW TIRBANIBULIN WORKS IN THE TREATMENT OF AREAS LARGER THAN 25 CM2 AND UP TO 100 CM2 OF THE FACE OR SCALP CONTAINING ACTINIC KERATOSIS LESIONS.
Status
In recruitment
headquarters
Pamplona/Madrid
Technical Summary
- PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, VEHICLE-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRBANIBULIN 10 MG/G OINTMENT APPLIED TO A TREATMENT FIELD GREATER THAN 25 CM2 AND UP TO 100 CM2 IN ADULT PATIENTS WITH ACTINIC KERATOSIS.
- Code EudraCT: 2023-505487-11-00
- Protocol number: M-14867-33
- Promoter: Almirall S.A
- Molecule/Drug: Tirbanibulin
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.